2012
DOI: 10.2147/ijn.s32367
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Background:The neurotrophic receptor tyrosine kinase B (TrkB) has diverse signaling roles in neurons and tumor cells. Accordingly, its suppressive targeting is of interest in neuroblastoma and other tumors, whereas its role in improving survival is focused in neurons. Here we describe targeting of TrkB-binding peptide-conjugated liposomes (PCL) to the TrkB-expressing mouse macrophage-like cell line RAW264, and to all-trans-retinoic acid-treated neuron-like TrkB Conclusion:We demonstrate here the feasibility o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
5
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 40 publications
(54 reference statements)
1
5
0
Order By: Relevance
“…The specificity of synthesized RNYK binding to the native NTRK2 by flow cytometry was similar to that reported by Ranjan et al 33 using an NTRK2-specifc antibody. The next phase of our experiments was performed in vitro to assess the neuroprotective potential of RNYK.…”
Section: Discussionsupporting
confidence: 86%
“…The specificity of synthesized RNYK binding to the native NTRK2 by flow cytometry was similar to that reported by Ranjan et al 33 using an NTRK2-specifc antibody. The next phase of our experiments was performed in vitro to assess the neuroprotective potential of RNYK.…”
Section: Discussionsupporting
confidence: 86%
“…Polymerosomes, lipid core nanocapsules (LNCs), silica as well as quantum dot NPs (QDotNPs) were used for the presented study. Peptide ligands are summarized in Figure 5 and described previously (Ranjan et al, 2012 ). 29D7 monoclonal anti-TrkB-antibody was kindly provided by Wyeth Research, Pfizer®, Connecticut, USA and characterized previously (Steketee et al, 2011 ).…”
Section: Methodsmentioning
confidence: 99%
“…The neuroblastoma cell line SH-SY5Y was differentiated by all-trans-retinoic acid (ATRA) treatment that induces expression of TrkB, but not of TrkA receptor, and mediates biological responsiveness to receptors for the neurotrophins BDNF and NT-4/5 as described previously by our group (Ranjan et al, 2012 ). As an alternative to SH-SY5Y cells, stable TrkB-transfected G7 cells were received from Garrett Brodeur, M.D.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations